Legal & General Group Plc Buys 11,715 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Legal & General Group Plc increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,514,237 shares of the medical research company’s stock after buying an additional 11,715 shares during the quarter. Legal & General Group Plc owned 0.83% of IQVIA worth $320,170,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Versant Capital Management Inc boosted its stake in shares of IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC bought a new position in IQVIA during the 2nd quarter valued at about $27,000. Itau Unibanco Holding S.A. bought a new position in IQVIA during the 2nd quarter valued at about $29,000. Rise Advisors LLC bought a new stake in IQVIA during the first quarter worth about $31,000. Finally, Riverview Trust Co acquired a new stake in shares of IQVIA during the first quarter worth approximately $32,000. 89.62% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on IQV shares. JPMorgan Chase & Co. boosted their target price on IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a report on Monday, August 5th. UBS Group increased their target price on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Royal Bank of Canada assumed coverage on IQVIA in a report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price target for the company. Truist Financial increased their price objective on shares of IQVIA from $292.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, July 23rd. Finally, The Goldman Sachs Group initiated coverage on shares of IQVIA in a research note on Thursday, June 6th. They issued a “buy” rating and a $270.00 target price for the company. Five investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $267.00.

IQVIA Price Performance

IQV opened at $234.79 on Friday. The company has a fifty day moving average price of $241.49 and a two-hundred day moving average price of $233.52. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The firm has a market capitalization of $42.80 billion, a PE ratio of 32.08, a P/E/G ratio of 2.25 and a beta of 1.49. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The business had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. During the same quarter in the prior year, the company posted $2.22 earnings per share. The firm’s revenue was up 2.3% on a year-over-year basis. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.